Hypertension enhances Aβ-induced neurovascular dysfunction, promotes β-secretase activity, and leads to amyloidogenic processing of APP

[1]  E. Hamel.  Cerebral Circulation: Function and Dysfunction in Alzheimer's Disease , 2015, Journal of cardiovascular pharmacology.

[2]  Arthur W. Toga,et al.  Blood-Brain Barrier Breakdown in the Aging Human Hippocampus , 2015, Neuron.

[3]  E. Dere,et al.  Hypertension Accelerates the Progression of Alzheimer-Like Pathology in a Mouse Model of the Disease , 2015, Hypertension.

[4]  L. Pantoni,et al.  Treatment of vascular risk factors in patients with a diagnosis of Alzheimer’s disease: a systematic review , 2014, BMC Medicine.

[5]  Jeffrey A. James,et al.  Cerebral perfusion alterations and cerebral amyloid in autosomal dominant Alzheimer disease , 2014, Neurology.

[6]  M. Pletcher,et al.  Early Adult to Midlife Cardiovascular Risk Factors and Cognitive Function , 2014, Circulation.

[7]  Kristine Yaffe,et al.  New insights into the dementia epidemic. , 2013, The New England journal of medicine.

[8]  C. Iadecola,et al.  The Pathobiology of Vascular Dementia , 2013, Neuron.

[9]  C. Iadecola,et al.  Hypertension: A Harbinger of Stroke and Dementia , 2013, Hypertension.

[10]  C. Iadecola,et al.  Circulating Endothelin-1 Alters Critical Mechanisms Regulating Cerebral Microcirculation , 2013, Hypertension.

[11]  D. Sosnowska,et al.  Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in β-amyloid generation and Alzheimer's disease. , 2013, American journal of physiology. Heart and circulatory physiology.

[12]  Denise C. Park,et al.  Risk factors for β-amyloid deposition in healthy aging: vascular and genetic effects. , 2013, JAMA neurology.

[13]  T. Reudelhuber.  Where hypertension happens. , 2013, The Journal of clinical investigation.

[14]  B. Zlokovic.  Cerebrovascular effects of apolipoprotein E: implications for Alzheimer disease. , 2013, JAMA neurology.

[15]  J. Pierce,et al.  Innate immunity receptor CD36 promotes cerebral amyloid angiopathy , 2013, Proceedings of the National Academy of Sciences.

[16]  C. Iadecola,et al.  Brain and Circulating Levels of A&bgr;1–40 Differentially Contribute to Vasomotor Dysfunction in the Mouse Brain , 2013, Stroke.

[17]  P. Greengard,et al.  Small‐molecule inducers of Aβ‐42 peptide production share a common mechanism of action , 2012, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  B. Zlokovic,et al.  Hypertension Induces Brain &bgr;-Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature , 2012, Hypertension.

[19]  C. Iadecola,et al.  Central Cardiovascular Circuits Contribute to the Neurovascular Dysfunction in Angiotensin II Hypertension , 2012, The Journal of Neuroscience.

[20]  L. Mucke,et al.  Alzheimer Mechanisms and Therapeutic Strategies , 2012, Cell.

[21]  B. Zlokovic.  Neurovascular pathways to neurodegeneration in Alzheimer's disease and other disorders , 2011, Nature Reviews Neuroscience.

[22]  T. Coffman,et al.  Under pressure: the search for the essential mechanisms of hypertension , 2011, Nature Medicine.

[23]  C. Iadecola,et al.  Scavenger receptor CD36 is essential for the cerebrovascular oxidative stress and neurovascular dysfunction induced by amyloid-β , 2011, Proceedings of the National Academy of Sciences.

[24]  D. Davis,et al.  Angiotensinergic Signaling in the Brain Mediates Metabolic Effects of Deoxycorticosterone (DOCA)-Salt in C57 Mice , 2011, Hypertension.

[25]  Inna Kuperstein,et al.  Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio , 2010, The EMBO journal.

[26]  B. Strooper,et al.  The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.

[27]  D. Leys,et al.  Treatment of vascular risk factors is associated with slower decline in Alzheimer disease , 2009, Neurology.

[28]  V. Haroutunian,et al.  Less Alzheimer disease neuropathology in medicated hypertensive than nonhypertensive persons , 2009, Neurology.

[29]  Wei Zhao,et al.  Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. , 2007, The Journal of clinical investigation.

[30]  Hong Qing,et al.  Hypoxia facilitates Alzheimer's disease pathogenesis by up-regulating BACE1 gene expression , 2006, Proceedings of the National Academy of Sciences.

[31]  T. Imaizumi,et al.  Telmisartan inhibits expression of a receptor for advanced glycation end products (RAGE) in angiotensin-II-exposed endothelial cells and decreases serum levels of soluble RAGE in patients with essential hypertension. , 2005, Microvascular research.

[32]  C. Iadecola,et al.  Angiotensin II Impairs Neurovascular Coupling in Neocortex Through NADPH Oxidase–Derived Radicals , 2004, Circulation research.

[33]  C. Iadecola.  Neurovascular regulation in the normal brain and in Alzheimer's disease , 2004, Nature Reviews Neuroscience.

[34]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[35]  Mikio Shoji,et al.  Age-Dependent Changes in Brain, CSF, and Plasma Amyloid β Protein in the Tg2576 Transgenic Mouse Model of Alzheimer's Disease , 2001, The Journal of Neuroscience.

[36]  F. Gejyo,et al.  Interaction between Aβ (1-42) and Aβ (1-40) in Alzheimer's β-amyloid fibril formation in vitro , 1999 .

[37]  D. Borchelt,et al.  SOD1 rescues cerebral endothelial dysfunction in mice overexpressing amyloid precursor protein , 1999, Nature Neuroscience.

[38]  Christina E. Wierenga,et al.  Cerebral blood flow measured by arterial spin labeling MRI as a preclinical marker of Alzheimer's disease. , 2014, Journal of Alzheimer's disease : JAD.

[39]  B. Zlokovic,et al.  Hypertension & Cognitive Impairment Hypertension Induces Brain -Amyloid Accumulation, Cognitive Impairment, and Memory Deterioration Through Activation of Receptor for Advanced Glycation End Products in Brain Vasculature , 2012 .

[40]  C. Iadecola,et al.  The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. , 2011, American journal of physiology. Heart and circulatory physiology.

[41]  D. Bennett,et al.  AHA / ASA Scientific Statement Vascular Contributions to Cognitive Impairment and Dementia , 2011 .

[42]  S. Younkin,et al.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. , 2001, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[43]  F. Gejyo,et al.  Interaction between A beta(1-42) and A beta(1-40) in Alzheimer's beta-amyloid fibril formation in vitro. , 1999, Biochemistry.